In this issue:
Afuresertib in MM
VCD vs. VTD induction in newly diagnosed transplanteligible MM
Post-SCT outcomes in MM with skeletal vs. soft-tissue plasmacytoma
Panobinostat with bortezomib and dexamethasone in MM
Lenalidomide and dexamethasone in transplant-ineligible MM
Ixazomib in relapsed/ refractory MM
Clinical course of light-chain smouldering MM
Uninvolved immunoglobulin levels and outcomes in symptomatic MM
Please login below to download this issue (PDF)